A Canadian cannabis firm with Australian operations has become one of the latest players to be approved for cannabis cultivation in Australia.

Ontario-based MPX International (CSE:MPXI,OTC Pink:MPXOF) confirmed on Monday (January 27) that its wholly owned subsidiary MPX Australia has been granted a medicinal cannabis licence by the Australian Office of Drug Control (ODC).


With the newly issued licence, MPX Australia will be able cultivate medical cannabis and produce cannabis resin, as well as test, package and ship its products from its 70,000 square foot cultivation facility in Launceston, Tasmania, which is still under construction.

 

Fear And Debt Push Gold To New Heights In 2020. What's Coming In 2021?

   
All The Answers You NEED In Our Precious Metals Outlook Report!
Grab Your FREE Report Today!
 

MPX International has experienced an upswing in value since it announced its subsidiary is breaking into the Australian cannabis sector. It went up 10.9 percent from the beginning of the week to the start of the trading session on Tuesday (January 28). As of 9:35 a.m. EST, shares sat at C$0.36.

Scott Boyes, CEO of MPX International, said in a press release that Australia will act as a crucial entry point for the company into the larger Oceania and Asia-Pacific cannabis markets.

After selling its US assets to multi-state operator iAnthus (CSE:IAN,OTCQX:ITHUF), MPX is emphasizing its focus as an international cannabis player.

Executive Director Tibor Vertes echoed the sentiment from Boyes, adding that MPX Australia offers a “strong foothold” into the country’s nascent marijuana industry.

mpx international stock chart jan 28

Vertes also said the company wants its new Australian licence to lead to the creation of brand awareness and a possible future export gateway for its Australian subsidiary.

The firm told investors about another licence approval in November 2019, when it got its hands on an official manufacture licence from the ODC for its Tasmania facility.

The site is scheduled to be in production by mid-2020, and it will be outfitted for indoor cultivation, extraction and manufacturing of medical cannabis products, according to Boyes.

Boyes credited Tasmania’s reputation for high-quality organic products and its supportive local government as key points in choosing the island for the base of its Australian operations.

In its Q3 2019 results, MPX International reported total revenue at C$674,745, while showing a net loss from operating activities of C$6.3 million.

Don’t forget to follow us @INN_Australia for real-time news updates!

Securities Disclosure: I, Danielle Edwards, hold no direct investment interest in any company mentioned in this article.

 

BRAND NEW! Take Advantage Of Silver On The Rise Before It's Too Late

   
PROMISING Stock Picks! EXCLUSIVE Interviews! JUST RELEASED Trends!
   
Everything You Need To Watch The Dollars Come Pouring In!
 

An Emerging Markets Sponsored Commentary

A report just released in early April confirms that the cannabis beverage sector is thriving. According to this report from industry stalwart, Marijuana Business Daily while sales for vapes, pre-rolls and flower were lackluster, cannabis beverages shined:

Keep reading... Show less

BevCanna Enterprises (CSE:BEV,OTCQQ:BVNNF,FWB:7BC) CEO Marcello Leone shared how the company is scaling up its products to forge partnerships and explore opportunities across Canada, the US and Western Europe. 

“Getting your standard processing license and being fully compliant at a federal level is critical in Canada, and we were successful in getting that done. Now we’re getting ready to launch our Keef line of beverages within the next 45 days,” Leone said. 

As a young company, Leone said BevCanna has only started, but it took a four-pronged approach to make sure that it is a revenue-generating company prepared for the opening of many jurisdictions for CBD-based products.

“We are blessed that we have a beautiful infrastructure of our own, a state-of-the-art bottling facility with a capacity of almost 200 million bottles per annum and a strong balance sheet of $55 million. We are in a strong position to scale and grow this company.”

BevCanna has received a Standard Processing License from Health Canada and is now fully authorized to begin production at its full-service, high-capacity beverage manufacturing facility. The company will begin production of its white-label products, number one US cannabis beverage brand Keef and its in-house beverages through licensed Canadian retailers, positioning the company to fully capitalize on the burgeoning Canadian cannabis-infused beverage sector.

Watch the full interview with CEO Marcello Leone above.

Keep reading... Show less

BioHarvest Sciences (CSE: BHSC) will be presenting at the Benzinga Cleantech Small Cap Conference taking place on April 22, 2021. We invite our shareholders and all interested parties to explore cleantech small cap investment opportunities through two days of networking, dealmaking and discovery.

Sign up to get a free spectator pass for the event: https://www.benzinga.com/events/small-cap/clean-tech/

Keep reading... Show less

Positive distributor feedback and strong consumer interest accelerating launch with distributors

Emerging leader in innovative health and wellness beverages and products, BevCanna Enterprises Inc. ( CSE:BEV , Q:BVNNF , FSE:7BC ) (“ BevCanna ” or the “ Company ”) announces today that its wholly-owned subsidiary Naturo Group has successfully completed its initial shipment of TRACE plant-based products to one of Japan’s largest beverage distributors.

Keep reading... Show less

Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco Labs” or the “Company”), a vertically integrated multistate operator and the number one U.S. wholesaler of branded cannabis products, today announced an additional refreshment of its board of directors to further strengthen its leadership in the cannabis industry.

Keep reading... Show less